汉森制药12月19日获融资买入760.74万元，融资余额1.46亿元

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical experienced a 2.71% increase in stock price on December 19, with a trading volume of 66.22 million yuan, indicating positive market sentiment [1] - On December 19, Hansen Pharmaceutical had a financing buy amount of 7.61 million yuan and a financing repayment of 10.93 million yuan, resulting in a net financing buy of -3.32 million yuan [1] - As of December 19, the total balance of margin trading for Hansen Pharmaceutical was 146 million yuan, which represents 4.25% of its circulating market value, indicating a relatively high level compared to the past year [1] Group 2 - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The main revenue sources for Hansen Pharmaceutical include: Si Mo Tang oral liquid (54.81%), Tian Ma Xing Nao capsules (23.38%), and others, with a total revenue of 741 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 6.75% [2] - The net profit attributable to the parent company for the same period was 82.53 million yuan, showing a year-on-year decrease of 36.88% [2] Group 3 - Hansen Pharmaceutical has distributed a total of 485 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for Hansen Pharmaceutical was 24,100, an increase of 0.85% from the previous period [3] - The eighth largest circulating shareholder is Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund, holding 2.11 million shares as a new shareholder [3]